Daurismo is a medication that has been approved by the FDA for the treatment of acute myeloid leukemia (AML) in adult patients who are 75 years or older, or who have other health conditions that prevent them from receiving intensive chemotherapy. This drug works by inhibiting a protein called BCL-2, which is overexpressed in AML cells and helps them survive and resist treatment.

It is important to note that Daurismo is not a standalone treatment for AML, but is used in combination with low-dose cytarabine, another chemotherapy drug. This combination has been shown to improve overall survival in older patients with AML who are not candidates for intensive chemotherapy.

As with any medication, Daurismo can cause side effects. Some common side effects include low blood cell counts, fatigue, nausea, and diarrhea. It is important to discuss any potential side effects with your healthcare provider before starting treatment.

It is also important to follow your healthcare provider’s instructions carefully when taking Daurismo. This medication is typically given as an injection under the skin once a week for three weeks, followed by a one-week break. Your healthcare provider will determine the best dosing schedule for you based on your individual needs and response to treatment.

If you have been diagnosed with AML and are not a candidate for intensive chemotherapy, Daurismo may be a treatment option for you. Talk to your healthcare provider to see if this medication is right for you and to learn more about the potential benefits and risks of treatment.